anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Resilience can be defined as the capacity to maintain performance or bounce back to normal functioning after a perturbation, and studying fluctuations in daily feed intake may be an effective way to identify resilient dairy cows. Our goal was to develop new phenotypes based on daily dry matter intake (DMI) consistency in Holstein cows, estimate genetic parameters and genetic correlations with feed efficiency and milk yield consistency, and evaluate their relationships with production, longevity, health, and reproduction traits. Data consisted of 397,334 daily DMI records of 6,238 lactating Holstein cows collected from 2007 to 2022 at 6 research stations across the United States. Consistency phenotypes were calculated based on the deviations from expected daily DMI for individual cows during their respective feeding trials, which ranged from 27 to 151 d in duration. Expected values were derived from different models, including simple average, quadratic and cubic quantile regression with a 0.5 quantile, and locally estimated scatterplot smoothing (LOESS) regression with span parameters 0.5 and 0.7. We then calculated the log of variance (log-Var-DMI) of daily deviations for each model as the consistency phenotype. Consistency of milk yield was also calculated, as a reference, using the same methods (log-Var-Milk). Genetic parameters were estimated using an animal model, including lactation, days in milk and cohort as fixed effects, and animal as random effect. Relationships between log-Var-DMI and traits currently considered in the US national genetic evaluation were evaluated using Spearman's rank correlations between sires' breeding values. Heritability estimates for log-Var-DMI ranged from 0.11 ± 0.02 to 0.14 ± 0.02 across models. Different methods (simple average, quantile regressions, and LOESS regressions) used to calculate log-Var-DMI yielded very similar results, with genetic correlations ranging from 0.94 to 0.99. Estimated genetic correlations between log-Var-DMI and log-Var-Milk ranged from 0.51 to 0.62. Estimated genetic correlations between log-Var-DMI and feed efficiency ranged from 0.55 to 0.60 with secreted milk energy, from 0.59 to 0.63 with metabolic body weight, and from 0.26 to 0.31 with residual feed intake (RFI). Relationships between log-Var-DMI and the traits in the national genetic evaluation were moderate and positive correlations with milk yield (0.20 to 0.21), moderate and negative correlations with female fertility (-0.07 to -0.20), no significant correlations with health and longevity, and favorable correlations with feed efficiency (-0.23 to -0.25 with feed saved and 0.21 to 0.26 with RFI). We concluded that DMI consistency is heritable and may be an indicator of resilience. Cows with lower variation in the difference between actual and expected daily DMI (more consistency) may be more effective in maintaining performance in the face of challenges or perturbations, whereas cows with greater variation in observed versus expected daily DMI (less consistency) are less feed efficient and may be less resilient.
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish a non-invasive way to filter high liver transplantation recipient population before transplantation. Based on large scales of pre-treatment MR images, the investigator's study aims to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population. This study will contribute to the precise selection of HCC-related liver transplantation recipients.
Participants will then undergo pre-intervention testing, with at least 20 minutes of rest between each. Once these tests are complete, the participant will ingest citalopram (40 mg) Then three hours later all tests will be conducted again. Participants will remain in the lab and will be free to read or work during this resting 3 hour period. This will conclude this experimental visit.
The cluster randomized controlled trial will be conducted in Bangkok communities supported by Thaicare. A total number of 70,000 participants will be enrolled from 70 clusters. (1,000 from each cluster). Participants from each area will be divided into three groups according to the accommodation type. The rational between intervention group 1 to intervention group 2 and control group will be 1:1:1. The characteristics of population in each stratum will be reproduced as closely as possible. Cluster randomization by software will be used to blind the order of randomization. Demographic data (i.e., age, gender, weight, height, body mass index), concomitant diseases, income, type of accommodation, vaccination profile) of the control and intervention groups will be collected. The collection of data and the obtaining of the consent will be conducted by Socialgiver volunteers. There will be 2 intervention groups. Group 1 will receive 4 rapid antigen kits at the beginning of the study and will be asked to conduct a weekly self-test for 3 weeks. Group 2 will receive 7 rapid antigen kits at the beginning of the study and will be asked to conduct a twice-weekly self-test for 3 weeks (total of 6 tests)
The nasopharyngeal suction with negative pressure method was employed in the control group in this study. In this method, the nasal secretions were softened with 1-2 ml of physiological saline (PS), and then negative pressure suction was performed using a pine-tipped suction set. In the literature, neonatal aspiration pressure is defined as 60-100 mmHg. In this study, the suction pressure was kept between 60 and 80 mmHg, and no suction lasted for more than 15 seconds.
The TAU condition will serve as the control condition and participants' medication use and outside therapies will be tracked monthly. Following completion of the 16-week wait period, the TAU group will be invited to enroll in FYF:ASD/ID.
NEW MATERIAL:A peptide shown by the formula. USE:An antihypertensive agent having excellently inhibitory activity against an enzyme capable of converting angiotensin. PREPARATION:First, tissue of fish (preferably Sardinops melanostieta) is extracted with distilled water and the extracted solution is centrifuged. Then ammonium sulfate is added to the prepared supernatant liquid until ammonium sulfate is saturated 70%. Formed precipitate is removed, ammonium sulfate is added to the supernatant liquid until ammonium sulfate is saturated 100% and formed precipitate is recovered. Successively, the precipitate is dissolved in distilled water, treated with a protease (preferably pepsin) and purified by ion exchange chromatography, gel filtration chromatography, etc.
The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should "assist her to evaluate threats to personal safety and make referrals as needed". There is a prompt to be mindful of client safety, and to make referrals as needed.
The present invention relates to the application of the cluytyl alcohol in the medicine, which prevents hypoxia pulmonary artery hypertension. The present invention is characterized in the following feathers. The extracted cluytyl alcoholwith purity of more than 98 percentages is mixed with the carboxymethyl starch, which is a disintegrant before packaging in the capsule. Each capsule contains 10mg cluytyl alcohol and 0.3mg carboxymethyl starch. The present invention can effectively prevent the hypoxia pulmonary artery hypertension and can effectively prevent the pulmonary vascular structural remodeling caused by hypoxia. The present invention has the functions of preventing the high altitude heart disease and the cor pulmonale.
This study will evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens as part of the HVTN 205 study.

Participants in this study will be assigned to one of five groups based on their previous vaccine regimen received in HVTN 205. Depending on their group, participants will receive the MVA/HIV62B vaccine, the AIDSVAX B/E vaccine, or both the MVA/HIV62B vaccine and the AIDSVAX B/E vaccine. All participants will receive their assigned vaccines at study entry (Day 0) and Month 4. Participants will attend several study visits through Month 10. Visits will include physical examinations, blood collection, HIV testing and risk reduction counseling, and interviews and questionnaires. Optional procedures at some visits include collection of rectal fluids, cervical fluids, and semen. Study staff will contact participants 2 years following the initial study injection for follow-up health monitoring.
Alcohol dependence (AD) is a chronic and relapsing condition affecting 10 million Americans. To date, only four pharmacotherapies are approved by the FDA for the treatment of alcoholism and their efficacy is modest. Therefore, medication development for AD represents a high priority area. Ibudilast (IBUD) is a glial cell modulator that inhibits phosphodiesterases (PDE) -4 and -10 and macrophage migration inhibitory factor (MIF). Preclinical data suggest that neuroimmune modulation is critical to the rewarding properties of drugs of abuse, including alcohol. Further, IBUD has been shown to enhance GDNF release in vivo and GDNF modulation has been implicated in alcohol reinstatement in animals, while PDE inhibition has been shown to reduce alcohol intake in mice. Together, these findings suggest that neuroimmune modulation constitutes a novel target for the treatment of alcoholism. The objective of this study is to advance medication development for alcoholism by conducting an initial Phase II study of IBUD for AD. Specifically, the proposed study consists of a randomized, double-blind, placebo-controlled within-subject crossover design to determine the safety, tolerability, and initial human laboratory efficacy of IBUD in a sample of 24 non-treatment seeking individuals with either alcohol abuse or dependence treated with IBUD (50mg BID) and placebo. Participants will complete two separate 7-day inpatient stays at the UCLA CTRC during which they will take the study medication, complete an IV alcohol challenge, and take part in a stress-exposure and cue-exposure paradigms. Specific aims are to test whether IBUD (a) is safe in the context of alcohol administration, (b) attenuates alcohol-induced reinforcement, and (c) dampens stress-induced and cue-induced alcohol craving. In sum, this study will efficiently evaluate safety and initial efficacy of IBUD thereby screening novel medications for AD and elucidating potential mechanisms by which IBUD may be clinically efficacious. Results from this study will inform whether a randomized controlled trial of IBUD for alcoholism is warranted.
General: Use with caution in patients with gastrointestinal, neurological, or blood disorders, and in those with a sensitivity to quinine.

Hepatic/Renal Disease: Antimalarial compounds should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs. A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs.

Hematologic Effects/Laboratory Tests: Antimalarial compounds should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs. Periodic blood cell counts should be performed if patients are given prolonged therapy. If any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, appears which is not attributable to the disease under treatment, consider discontinuation of hydroxychloroquine sulfate.

Hydroxychloroquine sulfate should be administered with caution in patients having glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

Dermatologic Effects: Dermatologic reactions to hydroxychloroquine sulfate may occur and, therefore, proper care should be exercised when it is administered to any patient receiving a drug with a significant tendency to produce dermatitis.
BACKGROUND Renal osteodystrophy is a serious complication of advanced chronic kidney disease (CKD). It predisposes the patient to fragility fracture and an increased risk of mortality. CASE REPORT We present the case of a 50-year-old male patient with stage 4 CKD and consequent renal osteodystrophy, who presented with a history of a recent provoked seizure, a severe electrolyte imbalance, and excruciating pain in the hip region. He had no history of a fall or trauma. A radiographic evaluation confirmed the rare finding of a bilateral femoral neck fracture. Upon stabilizing the patient, he was surgically managed with a bilateral hemiarthroplasty. A postoperative radiograph revealed a well-fixed prosthesis with no post-surgical complications. The patient had a full recovery. At the last follow-up visit, the patient was fully functional and had resumed normal activities. CONCLUSIONS This is a rare report with unusual mechanism of injury, involving a case of bilateral femoral neck fragility fractures, secondary to renal osteodystrophy in a stage 4 CKD patient. It draws the attention of medical care providers to the high risk of femoral fragility fractures that are secondary to renal osteodystrophy. Hemiarthroplasty is a safe and highly efficacious surgical option for managing such cases. This case also reiterates the dire need for greater public awareness and knowledge of CKD. Early diagnosis and treatment can substantially mitigate the associated morbidity and mortality.
All exercise training will take place at the Gathering Place, Beachwood OH, in the new Wellness Center that is equipped with state-of-the-art aerobic and resistance training apparati. All exercise will be performed under the supervision of the Gathering Place trained and certified staff. The patient group will perform a 20 week aerobic and resistance exercise training program to evaluate (compared to baseline) changes: in body composition (fat, lean tissue and bone mass); cytokines including insulin, leptin, adiponectin, IL-6, and TNFα; oxidative stress including urine isoprostane; cardiorespiratory fitness (VO2max); upper and lower body strength (assessed using a dynamometer); sleep (assessed using the Pittsburgh Sleep Quality Index \[PSQI\]); fatigue and quality of life (Qol) (assessed using the SF-36, FACIT instruments). Patients will be evaluated before and after a 20 week intervention and a 10 week post-intervention period. Participants also will be evaluated for motivation barriers and compliance. These feasibility parameters will provide the basis and guidance for an NCI grant application to focus on mechanisms and extend our evaluation to larger cohorts of African-American patients.
The predominant form of chronic renal disease associated with long-term lithium treatment is a chronic tubulointerstitial nephropathy (CTIN). The biopsy findings in patients with lithium induced CTIN include tubular atrophy, interstitial fibrosis, sclerotic glomeruli, tubular dilation, and nephron atrophy with cyst formation. The relationship between renal function and morphologic changes and their association with lithium treatment has not been established. CTIN patients might present with nephrotic proteinuria (>3.0g/dL), worsening renal insufficiency and/or nephrogenic diabetes insipidus. Postmarketing cases consistent with nephrotic syndrome in patients with or without CTIN have also been reported. The biopsy findings in patients with nephrotic syndrome include minimal change disease and focal segmental glomerulosclerosis. The discontinuation of lithium in patients with nephrotic syndrome has resulted in remission of nephrotic syndrome.  
  
Kidney function should be assessed prior to and during lithium treatment. Routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine, creatinine clearance, or proteinuria). During lithium treatment, progressive or sudden changes in renal function, even within the normal range, indicate the need for re­-evaluation of treatment.
The invention relates to a lucid ganoderma and Chinese flowering crabapple tea and a preparation method thereof. The lucid ganoderma and Chinese flowering crabapple tea is a lucid ganoderma powder and Chinese flowering crabapple tea bag or a lucid ganoderma spore powder and Chinese flowering crabapple tea bag or a fermented lucid ganoderma and Chinese flowering crabapple tea bag. The lucid ganoderma and Chinese flowering crabapple tea is a health-care product. The Chinese flowering crabapple tea is applied in treating or preventing in vitro hepatocyte damage, chronic alcoholic hepatocyte damage and breast cancer as well as reducing blood fat and blood glucose. The preparation process is simple, materials are easily obtained, and the application in health-care tea is considerable. The health-care tea has a good synergistic effect in CCL4-induced hepatocyte damage. In addition, the health-care tea has an obvious inhibiting effect on serum ALT (alanine aminotransferase) in mouse with chronic alcoholic hepatocyte damage, and shows a good synergistic effect. The lucid ganoderma and Chinese flowering crabapple tea can be widely promoted.
Argon Plasma Coagulation (APC) treatment will be delivered using a "spray-painting" technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation.
Oxaliplatin for Injection, USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, lyophilized powder for reconstitution. Lactose monohydrate is also present as an inactive ingredient.

NDC 67184-0501-1: 50 mg single-dose vial with flip-off seal individually packaged in a carton.  
NDC 67184-0502-1: 100 mg single-dose vial with flip-off seal individually packaged in a carton.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature].

Oxaliplatin for Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 The use of gloves is recommended. If a solution of Oxaliplatin for Injection, USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin for Injection, USP contacts the mucous membranes, flush thoroughly with water.
Recombinant viral vectors and compositions that include them for use as vehicles to induce an immunological response. Multivalent viral vectors may be used in compositions or vaccines containing one or more recombinant viral vectors for protection against a variety of pathogens. Formation of these viral vectors may include insertion and expression of foreign genes to protect against a variety of pathogens. Further provided are methods of making and using the recombinant viral vectors, as well as immunogenic compositions that include the vectors and/or antigens. In particular, immunogenic compositions may include recombinant viral vectors and/or antigens. In particular, immunogenic compositions may include recombinant viral vectors such as vHVT509, vHVT522, and/or vHVT523.
The cpds. of formula (I) (where R1 and R2 are H or lower alkoxy, or together form a methylene-dioxy gp. R3 is H or a carboxyl-protecting gp. R4 and R6 are H or lower alkoxy R5 is H or a phenol protecting gp. and R9 is phenyl as lower alkyl opt. substd. with one or more F, Cl or Br atoms) are made by cyclising a cyclopropyl cpd. of formula (II) with at least 0.5 equiv. of Lewis acid and at least one equiv. of acid anhydride (R9CO)2O (III)
A blood-sugar level analysis system includes a database, an input device, a processing device and a display device. The processing device is connected with the database, the input device and the display device. The processing device includes a blood-sugar recording module and an analysis module. The blood-sugar recording module obtains and records a user's blood-sugar level on at least a test time into the database. The analysis module obtains the user's blood-sugar level at the test time during an analysis period. Then, the analysis module analyzes the user's blood-sugar risk for the display device to display.
Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer, hi some embodiments, the methods include treatment or prevention of osteoporosis.
Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
According to the present invention, a self-produced skin gel pack package comprises N functional products and a base product. The N functional products comprise: N (N>=1) functional compositions containing designated functional components; and N functional container units storing the N functional compositions, wherein N functional compositions corresponding to the volumes of designated functional compositions in the maximum storage volume of the N functional container units are stored in internal accommodation spaces of the N functional container units. The base product comprises a base composition and a base container unit storing the base composition. The base composition contains a designated base component, is stored in a liquid state that can be mixed with the functional products, and is solidified under designated conditions to become a gel state, and be molded into a skin gel pack detachably attached to a designated skin area. The base product comprises a spare accommodation volume which is designated to be secured or securable in a volume range greater than or equal to the sum of the volumes of the N functional compositions. Accordingly, a purchase user can put the N functional compositions stored in the N functional container units in the maximum storage volume of the base container unit into the base container unit and mix the N functional compositions with the base composition. According to the present invention, a user can produce a customized skin gel pack optimized for his or her current skin condition.